Anja Koester

TL;DR: It is concluded that FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.

TL;DR: Systemic administration of FGF-21 reduced plasma glucose and triglycerides to near normal levels in genetically compromised diabetic rodents and led to significant improvements in lipoprotein profiles, including lowering of low-density lipop Protein cholesterol and raising of high-density Lipoprotein cholesterol.

TL;DR: The role of FGF21 is a critical regulator of long-term energy balance and metabolism as well as a physiological regulator that plays a role in lipid oxidation, as confirmed by mice generated with targeted disruption of the F GF21 locus.

TL;DR: These findings demonstrate that psychological "stress" is sensed by the innate immune system in the brain via the ATP/P2X7R-NLRP3 inflammasome cascade, and they identify novel therapeutic targets for the treatment of stress-related mood disorders and comorbid illnesses.

TL;DR: A long‐acting and efficacious GLP‐1 immunoglobulin G (IgG4) Fc fusion protein (LY2189265) with extended pharmacokinetics and activity is developed for type 2 diabetes treatment with a short half‐life.